Article Text

Download PDFPDF
Correlation of ocular rigidity with intraocular pressure spike after intravitreal injection of bevacizumab in exudative retinal disease
  1. Diane N Sayah1,2,
  2. Andrei-Alexandru Szigiato2,
  3. Javier Mazzaferri1,
  4. Denise Descovich1,
  5. Renaud Duval1,2,
  6. Flavio A Rezende1,2,
  7. Santiago Costantino1,2,
  8. Mark R Lesk1,2
  1. 1Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, Montreal, Quebec, Canada
  2. 2Ophthalmology, University of Montreal, Montreal, Quebec, Canada
  1. Correspondence to Dr Mark R Lesk, Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, Montreal, QC H1T 2M4, Canada; lesk{at}videotron.ca

Abstract

Background/aims To evaluate the non-invasive measurement of ocular rigidity (OR), an important biomechanical property of the eye, as a predictor of intraocular pressure (IOP) elevation after anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection (IVI).

Methods Subjects requiring IVI of anti-VEGF for a pre-existing retinal condition were enrolled in this prospective cross-sectional study. OR was assessed in 18 eyes of 18 participants by measurement of pulsatile choroidal volume change using video-rate optical coherence tomography, and pulsatile IOP change using dynamic contour tonometry. IOP was measured using Tono-Pen XL before and immediately following the injection and was correlated with OR.

Results The average increase in IOP following IVI was 19±9 mm Hg, with a range of 7–33 mm Hg. The Spearman correlation coefficient between OR and IOP elevation following IVI was 0.796 (p<0.001), showing higher IOP elevation in more rigid eyes. A regression line was also calculated to predict the IOP spike based on the OR coefficient, such that IOP spike=664.17 mm Hg·µL×OR + 4.59 mm Hg.

Conclusion This study shows a strong positive correlation between OR and acute IOP elevation following IVI. These findings indicate that the non-invasive measurement of OR could be an effective tool in identifying patients at risk of IOP spikes following IVI.

  • glaucoma
  • imaging
  • intraocular pressure
  • retina
  • treatment medical
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors DS, SC and ML designed the study. DS, DD, RD and FAR were involved in data collection. DS, A-AS, JM, SC and ML analysed and interpreted the data. DS and A-AS drafted the first manuscript.

  • Funding This work was supported by the Canadian Institutes of Health Research (grant number 311562, SC and ML); the Natural Sciences and Engineering Research Council of Canada (grant number RGPIN-2016–04227, SC); the Fonds de Recherche en Ophtalmologie de l’Université de Montréal (ML and SC), the Fonds de Recherche du Québec—Santé (SC and DS) and the Glaucoma Research Society of Canada (ML).

  • Competing interests None declared.

  • Patient consent for publication Informed consent was obtained from all participants prior to testing.

  • Ethics approval This study was approved by the Maisonneuve-Rosemont Hospital Institutional Review Board and conformed to the principles of the Declaration of Helsinki.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.